Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Drug Discovery & Development › Chi-Med Initiates Phase I Trial of HMPL-306 in Hematological Malignancies With IDH1/2 Mutations

Chi-Med Initiates Phase I Trial of HMPL-306 in Hematological Malignancies With IDH1/2 Mutations

Jul 24, 2020
|
staff reporter

NEW YORK − Hutchison Medipharma, a subsidiary of Chi-Med, said on Friday that it has started a Phase I trial in China for HMPL-306 in patients with IDH1 and IDH2-mutated relapsed or refractory myeloid leukemia or neoplasms and has dosed the first patient.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
08
Featured Webinar

Interpretation of Comprehensive Genomic Profiling from ctDNA Through Clinical Decision Support

Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.

What's Popular?

In Drug Discovery & Development

  1. Kronos Bio Doses First Patient in CDK9 Inhibitor Trial With Tempus Performing Sequencing

  2. Zentalis Pharmaceuticals, Tempus Partner to Explore WEE1 Inhibitor Activity in Organoid Models

  3. Celcuity Prices Upsized Public Stock Offering, Anticipates $24M in Proceeds

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.